Andrei A. Yarushkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrei A. Yarushkin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir O. Pustylnyak
Institute for the Medicine and Medical Technology, Novosibirsk State University, Pirogova Street, 1, Novosibirsk 630090, Russia
10 shared publications Yuliya A. Kazantseva
The Institute of Molecular Biology and Biophysics, Timakova str., 2/12, Novosibirsk 630117, Russia
5 shared publications- Lyudmila F. Gulyaeva
Institute for the Medicine and Medical Technology, Novosibirsk State University, Pirogova Street, 1, Novosibirsk 630090, Russia
3 shared publications Yuliya A. Pustylnyak
The Institute of Molecular Biology and Biophysics, Timakova str., 2/12, Novosibirsk 630117, Russia; Novosibirsk State University, Pirogova str., 1, Novosibirsk 630090, Russia
3 shared publications- Dmitry V. Yudkin
Federal Scientific and Technical Program on the Development of Genetic Technologies, State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Kol’tsovo, Russia
2 shared publications Nikolai Slynko
2 shared publications
Latest Publications
- Open Access
- 1 March 2021
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 6 (1) , 1-7
miRNA expression and interaction with the 3′UTR of FMR1 in FRAXopathy pathogenesis
FRAXopathies are caused by the expansion of the CGG repeat in the 5′UTR of the FMR1 gene, which encodes the protein responsible for the synthesis of FMRP. This mutation leads to dramatic changes in FMRP expression at both the mRNA and protein levels. Evidence is emerging that changes in FMR1 mRNA expression can lead to the dysregulation of the miRNAs that target its 3′UTR. In the present work, B-lymphocyte cell lines obtained from patients with FRAXopathies were used, and a wide variety of FMR1 gene activities were observed, allowing the identification of the relationships between FMR1 dysregulation and miRNA activity. We studied the expression levels of eight miRNAs that target the FMR1 gene. To prove the interaction of the studied miRNAs with FMR1, a plasmid was constructed that possesses three primary structures: the miRNA gene, with expression driven by an inducible promoter; a constitutively expressed FusionRed reporter; and an eGFP reporter followed by the 3′UTR of the FMR1 gene. We evaluated changes in miRNA expression in response to alterations in FMR1 gene activity in a model cell line as well as interactions with some miRNAs with the FMR1 3′UTR.
- 1 March 2021
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 6 (1) , 1-7
Open AccessmiRNA expression and interaction with the 3′UTR of FMR1 in FRAXopathy pathogenesis
FRAXopathies are caused by the expansion of the CGG repeat in the 5′UTR of the FMR1 gene, which encodes the protein responsible for the synthesis of FMRP. This mutation leads to dramatic changes in FMRP expression at both the mRNA and protein levels. Evidence is emerging that changes in FMR1 mRNA expression can lead to the dysregulation of the miRNAs that target its 3′UTR. In the present work, B-lymphocyte cell lines obtained from patients with FRAXopathies were used, and a wide variety of FMR1 gene activities were observed, allowing the identification of the relationships between FMR1 dysregulation and miRNA activity. We studied the expression levels of eight miRNAs that target the FMR1 gene. To prove the interaction of the studied miRNAs with FMR1, a plasmid was constructed that possesses three primary structures: the miRNA gene, with expression driven by an inducible promoter; a constitutively expressed FusionRed reporter; and an eGFP reporter followed by the 3′UTR of the FMR1 gene. We evaluated changes in miRNA expression in response to alterations in FMR1 gene activity in a model cell line as well as interactions with some miRNAs with the FMR1 3′UTR.
- 29 June 2020
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 30 (8) , 562-569
Downregulation of Acat1 by miR-21 may participate in liver fibrosis upon chronic DDT exposure
The main objective of the present study was to investigate the toxic effect of long-term exposure to DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane) on rat livers. Female Wistar rats were treated with once-weekly i.p. doses of DDT (10 and 50 mg/kg) for 12 weeks. Histological analysis revealed significant changes in the liver structure, especially at a dose of 50 mg/kg, which consistent with a fibrotic state. Long-term DDT exposure increased micro RNA-21 (miR-21) level and decreased Acetyl-CoA acetyltransferase 1 (Acat1) mRNA and protein levels in a dose-dependent manner. A dual-luciferase reporter assay confirmed the regulation of the rat Acat1 3′-UTR by miR-21. Previous studies have described the involvement of ACAT1 in fibrogenesis; thus, regulation of the Acat1 gene by miR-21 may play a role in DDT exposure-mediated liver fibrosis.
- 29 June 2020
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 30 (8) , 562-569
Downregulation of Acat1 by miR-21 may participate in liver fibrosis upon chronic DDT exposure
The main objective of the present study was to investigate the toxic effect of long-term exposure to DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane) on rat livers. Female Wistar rats were treated with once-weekly i.p. doses of DDT (10 and 50 mg/kg) for 12 weeks. Histological analysis revealed significant changes in the liver structure, especially at a dose of 50 mg/kg, which consistent with a fibrotic state. Long-term DDT exposure increased micro RNA-21 (miR-21) level and decreased Acetyl-CoA acetyltransferase 1 (Acat1) mRNA and protein levels in a dose-dependent manner. A dual-luciferase reporter assay confirmed the regulation of the rat Acat1 3′-UTR by miR-21. Previous studies have described the involvement of ACAT1 in fibrogenesis; thus, regulation of the Acat1 gene by miR-21 may play a role in DDT exposure-mediated liver fibrosis.
- Open Access
- 25 October 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-5
Inhibitors of Histone Deacetylases Are Weak Activators of the FMR1 Gene in Fragile X Syndrome Cell Lines
Fragile X syndrome is the most common cause of inherited intellectual disability in humans. It is a result of CGG repeat expansion in the 5′ untranslated region (5′ UTR) of the FMR1 gene. This gene encodes the FMRP protein that is involved in neuronal development. Repeat expansion leads to heterochromatinization of the promoter, gene silencing, and the subsequent absence of FMRP. To date, there is no specific therapy for the syndrome. All treatments in clinic practice provide symptomatic therapy. The development of drug therapy for Fragile X syndrome treatment is connected with the search for inhibitors of enzymes that are responsible for heterochromatinization. Here, we report a weak transcriptional activity of the FMR1 gene and the absence of FMRP protein after Fragile X syndrome cell lines treatment with two FDA approved inhibitors of histone deacetylases, romidepsin and vorinostat. We demonstrate that romidepsin, an inhibitor of class I histone deacetylases, does not activate FMR1 expression in patient cell cultures, whereas vorinostat, an inhibitor of classes I and II histone deacetylases, activates a low level of FMR1 expression in some patient cell lines.
- 25 October 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-5
Open AccessInhibitors of Histone Deacetylases Are Weak Activators of the FMR1 Gene in Fragile X Syndrome Cell Lines
Fragile X syndrome is the most common cause of inherited intellectual disability in humans. It is a result of CGG repeat expansion in the 5′ untranslated region (5′ UTR) of the FMR1 gene. This gene encodes the FMRP protein that is involved in neuronal development. Repeat expansion leads to heterochromatinization of the promoter, gene silencing, and the subsequent absence of FMRP. To date, there is no specific therapy for the syndrome. All treatments in clinic practice provide symptomatic therapy. The development of drug therapy for Fragile X syndrome treatment is connected with the search for inhibitors of enzymes that are responsible for heterochromatinization. Here, we report a weak transcriptional activity of the FMR1 gene and the absence of FMRP protein after Fragile X syndrome cell lines treatment with two FDA approved inhibitors of histone deacetylases, romidepsin and vorinostat. We demonstrate that romidepsin, an inhibitor of class I histone deacetylases, does not activate FMR1 expression in patient cell cultures, whereas vorinostat, an inhibitor of classes I and II histone deacetylases, activates a low level of FMR1 expression in some patient cell lines.
- 1 February 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 797, 39-44
Peroxisome proliferator-activated receptor γ activation inhibits liver growth through miR-122-mediated downregulation of cMyc
- 1 February 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 797, 39-44
Peroxisome proliferator-activated receptor γ activation inhibits liver growth through miR-122-mediated downregulation of cMyc
- 1 September 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (3) , 1099-1105
Constitutive androstane receptor activation evokes the expression of glycolytic genes
- 1 September 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (3) , 1099-1105
Constitutive androstane receptor activation evokes the expression of glycolytic genes
- 1 October 2015
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 288 (1) , 26-32
Xenosensor CAR mediates down-regulation of miR-122 and up-regulation of miR-122 targets in the liver
- 1 October 2015
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 288 (1) , 26-32
Xenosensor CAR mediates down-regulation of miR-122 and up-regulation of miR-122 targets in the liver
- 1 July 2014
- Published by Elsevier in Toxicology
- Vol. 321, 73-79
CAR-mediated repression of Foxo1 transcriptional activity regulates the cell cycle inhibitor p21 in mouse livers
- 1 July 2014
- Published by Elsevier in Toxicology
- Vol. 321, 73-79
CAR-mediated repression of Foxo1 transcriptional activity regulates the cell cycle inhibitor p21 in mouse livers
- 1 September 2013
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 271 (2) , 137-143
Dichlorodiphenyltrichloroethane technical mixture regulates cell cycle and apoptosis genes through the activation of CAR and ERα in mouse livers
- 1 September 2013
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 271 (2) , 137-143
Dichlorodiphenyltrichloroethane technical mixture regulates cell cycle and apoptosis genes through the activation of CAR and ERα in mouse livers
- Open Access
- 11 December 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 168 (8) , 1923-1932
The constitutive androstane receptor activator 4‐[(4R,6R)‐4,6‐diphenyl‐1,3‐dioxan‐2‐yl]‐N,N‐dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4α and FOXO1 transcriptional activity
Background and Purpose: The dual role of the constitutive androstane receptor (CAR) as both a xenosensor and a regulator of endogenous energy metabolism (lipogenesis and gluconeogenesis) has recently gained acceptance. Here, we investigated the effects of 4‐[(4R,6R)‐4,6‐diphenyl‐1,3‐dioxan‐2‐yl]‐N,N‐dimethylaniline (transpDMA), an effective CAR activator, on the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose‐6‐phosphatase (G6Pase) in rat livers.Experimental Approach: The effects of transpDMA were investigated in normal and high‐fat diet‐fed Wistar rats using real‐time PCR, Western blotting, chromatin immunoprecipitation assays (ChIP), glucose tolerance test and insulin tolerance test.Key Results: The expression of the gluconeogenic enzymes PEPCK and G6Pase was repressed by transpDMA treatment under fasting conditions. Long‐term CAR activation by transpDMA significantly reduced fasting blood glucose levels and improved glucose homeostasis and insulin sensitivity in high‐fat diet‐fed rats. The metabolic benefits of CAR activation by transpDMA may have resulted from the inhibition of hepatic gluconeogenic genes. ChIP assays demonstrated that transpDMA prevented the binding of forkhead box O1 (FOXO1) to insulin response sequences in the PEPCK and G6Pase gene promoters in rat livers. Moreover, transpDMA‐activated CAR inhibited hepatocyte nuclear factor‐4α (HNF4α) transactivation by competing with HNF4α for binding to the specific binding element (DR1‐site) in the gluconeogenic gene promoters.Conclusions and Implications: Our results provide evidence to support the conclusion that transpDMA inhibits the gluconeogenic genes PEPCK and G6Pase through suppression of HNF4α and FOXO1 transcriptional activity.
- 11 December 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 168 (8) , 1923-1932
Open AccessThe constitutive androstane receptor activator 4‐[(4R,6R)‐4,6‐diphenyl‐1,3‐dioxan‐2‐yl]‐N,N‐dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4α and FOXO1 transcriptional activity
Background and Purpose: The dual role of the constitutive androstane receptor (CAR) as both a xenosensor and a regulator of endogenous energy metabolism (lipogenesis and gluconeogenesis) has recently gained acceptance. Here, we investigated the effects of 4‐[(4R,6R)‐4,6‐diphenyl‐1,3‐dioxan‐2‐yl]‐N,N‐dimethylaniline (transpDMA), an effective CAR activator, on the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose‐6‐phosphatase (G6Pase) in rat livers.Experimental Approach: The effects of transpDMA were investigated in normal and high‐fat diet‐fed Wistar rats using real‐time PCR, Western blotting, chromatin immunoprecipitation assays (ChIP), glucose tolerance test and insulin tolerance test.Key Results: The expression of the gluconeogenic enzymes PEPCK and G6Pase was repressed by transpDMA treatment under fasting conditions. Long‐term CAR activation by transpDMA significantly reduced fasting blood glucose levels and improved glucose homeostasis and insulin sensitivity in high‐fat diet‐fed rats. The metabolic benefits of CAR activation by transpDMA may have resulted from the inhibition of hepatic gluconeogenic genes. ChIP assays demonstrated that transpDMA prevented the binding of forkhead box O1 (FOXO1) to insulin response sequences in the PEPCK and G6Pase gene promoters in rat livers. Moreover, transpDMA‐activated CAR inhibited hepatocyte nuclear factor‐4α (HNF4α) transactivation by competing with HNF4α for binding to the specific binding element (DR1‐site) in the gluconeogenic gene promoters.Conclusions and Implications: Our results provide evidence to support the conclusion that transpDMA inhibits the gluconeogenic genes PEPCK and G6Pase through suppression of HNF4α and FOXO1 transcriptional activity.
- 1 March 2012
- Published by Elsevier in European Journal of Pharmacology
- Vol. 679 (1-3) , 139-143
Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes
- 1 March 2012
- Published by Elsevier in European Journal of Pharmacology
- Vol. 679 (1-3) , 139-143
Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes